Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spectrin beta chain, non-erythrocytic 1 (SPTBN1, also known as beta-II spectrin) is an actin crosslinking and molecular scaffold protein that links the plasma membrane to the actin cytoskeleton, contributing to the determination of cell shape, the arrangement of transmembrane proteins, and the organization of organelles. SPTBN1 is part of the spectrin family, characterized by modular domains including actin-binding domains, spectrin repeats, and other motifs that allow it to mediate protein-protein interactions. It is predominantly expressed in all nucleated cells and plays a crucial role in neuronal and cardiac architecture, cell cycle regulation, and apoptosis. Dysfunction or deficiency in SPTBN1 has been associated with a spectrum of developmental and neurological disorders, but it is not considered a direct therapeutic target such as a receptor or enzyme[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spectrin beta chain, non-erythrocytic 1 (SPTBN1).